(Q35857847)

10 August 2017

1 reference

title

Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease (English)

1 reference

10 August 2017

0 references

Bytzer P

1

1 reference

10 August 2017

Blum AL

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Alimentary Pharmacology & Therapeutics

10 August 2017

published in

1 reference

10 August 2017

volume

20

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

389-398

1 reference

Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Helicobacter pylori infection and long term proton pump inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Gastric mucosal morphological consequences of acid suppression: a balanced view

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Symptoms in gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Empirical treatment based on "typical" reflux symptoms is inappropriate in a population with a high prevalence of Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02093.X

10.1111/J.1365-2036.2004.02093.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference